Innate Pharma ADR(IPHA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.59 | Insider Own | - | Shs Outstand | 93.9M | Perf Week | - |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 14.38% | Insider Trans | - | Shs Float | - | Perf Month | -7.98% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.15 | Inst Own | 0.17% | Short Float | - | Perf Quarter | -14.29% |
| Income | -0.06B | P/S | 33.92 | EPS this Y | 73.31% | Inst Trans | 4.27% | Short Ratio | 0.81 | Perf Half Y | 4.17% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -74.4% | Short Interest | 0.13M | Perf YTD | -14.29% |
| Book/sh | -0.49 | P/C | 13.45 | EPS past 3/5Y | 6.86% 7.69% | ROE | - | 52W High | -44.65% ($2.71) | Perf Year | -27.54% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | -60.77% -45.26% | ROIC | - | 52W Low | 28.21% ($1.17) | Perf 3Y | -39.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 1.17% | Gross Margin | - | Volatility(W/M) | 4.6% 5.99% | Perf 5Y | -74.14% |
| Dividend TTM | - | EV/Sales | 36.07 | Sales Y/Y TTM | -24.21% | Oper. Margin | -1257.04% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.6 | EPS Q/Q | 8.99% | Profit Margin | -1121.55% | RSI (14) | 43.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.6 | Sales Q/Q | 99.1% | SMA20 | -0.69% ($1.51) | Beta | 0.77 | Target Price | $6.73 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | -15.65% ($1.78) | Rel Volume | 0.03 | Prev Close | $1.52 |
| Employees | 163 | LT Debt/Eq | - | EPS/Sales Surpr. | 18.13% 2.38% | SMA200 | -12.58% ($1.72) | Avg Volume(3M) | 0.16M | Price | $1.5 |
| IPO | 2019/10/17 | Option/Short | No/Yes | Trades | 32 | Volume | 5,395 | Change | -1.32% |
A clinical-stage oncology-focused biotech headquartered in Marseille, France, that develops antibody therapeutics leveraging immune cells to attack cancer. Its pipeline includes monoclonal antibodies, antibody-drug conjugates, and multi-specific NK cell engagers based on its proprietary ANKET platform, with clinical advancement supported by collaborations with major pharmaceutical companies.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
Next earnings report: November 5
6 days to go.
IPHA has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,392. Peers typically go for $1,089.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.2%.
Tap to view numbers
It ranks #318 of 594 in the industry
Based on market cap of $168M.
ALXO#317 Alx Oncology Holdings Inc $169M PER - IPHA#318 Innate Pharma ADR $168M PER - 
VRXA#319 Veraxa Biotech AG $167M PER 5.3 
PEPG#320 PepGen Inc $167M PER - 
ABOS#321 Acumen Pharmaceuticals Inc $166M PER - 
FAQ
What kind of company is IPHA?
IPHA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IPHA?
The market cap of IPHA is approximately $168M, ranking 4,157 within its sector.
What is the 52-week high and low for IPHA?
IPHA has recorded a 52-week high of $2.71 and a low of $1.17.
